Evidence map›Paper›PMID 40943296›Full record

ArticleInternational journal of molecular sciences2025

The Generation of iPSCs Expressing Interferon-Beta Under Doxycycline-Inducible Control.

Olga Sheveleva, Nina Butorina, Elena Protasova, Sergey Medvedev, Elena Grigor'eva, Victoria Melnikova, Valeriia Kuziaeva, Marina Minzhenkova, Yana Tatarenko, Irina Lyadova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olga ShevelevaLaboratory of Cellular and Molecular Basis of Histogenesis, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.
Nina ButorinaLaboratory of Cellular and Molecular Basis of Histogenesis, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.
Elena ProtasovaLaboratory of Cellular and Molecular Basis of Histogenesis, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.ORCID 0000-0002-3457-4526
Sergey MedvedevLaboratory of Developmental Epigenetics, Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russia.ORCID 0000-0002-1520-5549
Elena Grigor'evaLaboratory of Developmental Epigenetics, Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russia.ORCID 0000-0002-9162-9108
Victoria MelnikovaLaboratory of Comparative Developmental Physiology, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.ORCID 0000-0003-2851-7039
Valeriia KuziaevaLaboratory of Cellular and Molecular Basis of Histogenesis, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.ORCID 0009-0008-5419-5217
Marina MinzhenkovaLaboratory of Cell Biology, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.ORCID 0000-0001-5458-0408
Yana TatarenkoLaboratory of Cell Biology, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.ORCID 0009-0005-7495-2623
Irina LyadovaLaboratory of Cellular and Molecular Basis of Histogenesis, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia.

Funding

government basic research program at the Koltzov Institute of Developmental Biology of the Russian Academy of Sciences in 2024 № 0088-2024-0013
6 · The paper itself

Abstract

Type 1 interferons (IFN-Is) exhibit significant antiviral, antitumor, and immunoregulatory properties, demonstrating substantial therapeutic potential. However, IFN-Is are pleiotropic cytokines, and the available data on their effect under specific pathological conditions are inconclusive. Furthermore, the systemic administration of IFN-Is can result in side effects. Generating cells that can migrate to the pathological focus and provide regulated local production of IFN-Is could overcome this limitation and provide a model for an in-depth analysis of the biological and therapeutic effects of IFN-Is. Induced pluripotent stem cells (iPSCs) are a valuable source of various differentiated cell types, including human immune cells. In this study, we describe the generation of genetically modified human iPSCs with doxycycline-controlled overexpression of interferon β (IFNB1). Three

Indexed as

DoxycyclineInduced Pluripotent Stem CellsInterferon-betaCell DifferentiationCell LineCRISPR-Cas SystemsHumansDoxycyclineInterferon-betaCRISPR/Cas9 technologydoxycycline-inducible gene expressioninduced pluripotent stem cellsinterferon-beta (IFN-β)trilineage differentiation

Identifiers

PMID40943296
PMCPMC12429120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.